The following technologies have been assessed and reviewed by our expert team and are currently available for licensing or sponsored research.

Best practice programs to support early-phase startups from idea to revenue.

  • Programs
    • Startup Primer

      Startup Primer

      Don't know where to start with your business idea? This workshop will prime you with the basics to help you move in the right direction. By the end of this workshop, you will walk away with a first draft of your business model, with input from an experienced startup advisor, which you can use to launch your venture. 

       

      Learn More Register
    • Discover

      Discover

      Understanding customer behaviour is essential to your startup success. This applied program teaches how to engage customers and discover their motivations, preferences and needs. 

       

      Learn more Register
    • Validate

      Validate

      This applied program will guide founders through the validation of a product and business model. By the end, you will have sufficient knowledge to decide whether the venture is viable, and if so, feel confident to begin sales and running a business. 

      Learn more Register
    • Go-To-Market

      Go-To-Market

      Maximize successful execution in market entry, product launch and revenue growth by addressing marketplace challenges and focusing on strategy and implementation.

      Learn more

    Programs

  • Accelerator Programs
    • Kinetica Ventures

      Kinetica Ventures

      Kinetica bridges the gap between the energy industry and energy technology developers/companies. We help to validate and curate energy startups making it easier for industry adoption or acquisition.

      Learn more
    • TEC Edmonton Health Accelerator

      TEC Edmonton Health Accelerator

      TEC Edmonton's Health accelerator is a bridge builder between the commercial medical world looking for new and improved health products.

      Learn more
    • TELUS Accelerator Program

      TELUS Accelerator Program

      We are currently not accepting applications. Contact us for more information about our next cohort.

      This six-month program is designed to accelerate your company's business model, technology and investment attraction. This program is available to growth-stage startups who are working on priority areas including big data, health and wellness, smart cities and digital oilfields. There is no cost to apply, no equity will be claimed on intellectual property that is developed within the accelerator. 

      Learn more
    • RBC Social Enterprise Accelerator Program

      RBC Social Enterprise Accelerator Program

      We are no longer accepting applications for 2016. Contact us for more information about our 2017 cohort.

      This eight-month program is designed to accelerate Calgary-based startups whose mission is to create social impact while ensuring that profitability is core to their business model. This is a competitive program open to startups, especially those with a focus on inclusive finance, poverty alleviation, affordable housing and integrating new immigrants.

      Learn more

    Accelerator Programs

  • Services
    • CEO Roundtable

      CEO Roundtable

      A monthly peer advisory forum for CEOs, board members and founders of technology companies to openly discuss their challenges in a confidential, safe environment. The goal of the roundtables are to provide "just-in-time" advice on current issues, enhance accountability and accelerate actions/decisions. 

      "This roundtable has transformed our company, period. There are not enough good things I can say about this group. Even banks recognize its significance toward the foundation for a strong company." - Jeremy Bridge

      Learn more Apply
    • Venture Mentoring Service of Alberta (VMSA)

      Venture Mentoring Service of Alberta (VMSA)

      Created to provide world-class mentoring to entrepreneurs throughout Alberta, this program will provide participants with a safe environment where mentors have no conflict of interest or financial interest. VMSA strongly believes that entrepreneurs matched with experienced entrepreneurs are more likely to succeed.

      Apply Learn more
    • Green Tech Mentors

      Green Tech Mentors

      Designed to accelerate the development of promising small and medium-size enterprises (SMEs) with a focus on the greenhouse gas (GHG) emissions in Alberta and beyond.

      GT Mentors connects SMEs to world-class mentors, executives and board members.

       

      Learn more
    • Intellectual Property Management

      Intellectual Property Management

      Professional patent management services for preparation, filing and prosecution. We guide all aspects of obtaining issued patents through our Canadian and U.S. patent firms.

       

      Learn more
    • Funding Support

      Funding Support

      Prepare your approach to venture financing through performing a "12 Point Business Assessment".

      Having a plan to fund your business from many sources, which may include equity investors, is just as important as your business plan.

      Apply

    Services

  • Space
    • Corporate ID | Virtual Space

      Corporate ID | Virtual Space

      The Corporate ID Service allows you to move your business beyond your home address or local coffee shop. Corporate ID clients are provided with a professional address, access to meeting rooms, business centre resources and reception services for a monthly rate.

      Enquire
    • The Inc.

      The Inc.

      The Inc. is a startup incubator program that combines one-on-one mentoring and co-working space to provide support and guidance for your unique startup. From open desk space to dedicated offices, this monthly membership offers you the flexibility you need to move your business forward.

      Learn more
    • Tenancy

      Tenancy

      Be part of the Alastair Ross Technology Centre community. We offer flexible leasing terms of office space from 250-square-foot to 3,000-square-foot.

      Enquire
    • Kinetica Innovation Centre at SAIT (KICS)

      Kinetica Innovation Centre at SAIT (KICS)

      A facility and program that helps clean energy technology startups and researchers design, prototype and test their proprietary technologies.

      KICS helps innovators move their idea from testing and experimentation to prototype development.

      Learn more Apply

    Space

Stay Up-To-Date

Join our mailing list

Parvus Therapeutics Announces Exclusive Worldwide Licence with Novartis

Wednesday, April 19, 2017

Innovate Calgary would like to congratulate Parvus Therapeutics Inc. on obtaining an exclusive licence and collaboration agreement with Novartis to advance the treatment of type 1 diabetes. 

 

Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes

CALGARY, Alberta — April 19, 2017 — Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes. Navacims are the first biopharmaceuticals to demonstrate in preclinical models the ability to restore immune tolerance in a disease-specific manner through in vivo formation and expansion of regulatory T-cells (T-regs) without causing general immune suppression.

Under the terms of the agreement, Novartis receives exclusive, worldwide rights to use Parvus’ Navacim technology to develop and commercialize products for the treatment of type 1 diabetes (T1D) and will be responsible for clinical-stage development and commercialization activities. Parvus will be primarily responsible for conducting the ongoing preclinical work for the T1D program and filing the IND in collaboration with Novartis through a joint steering committee. Parvus has received an upfront payment and will receive research funding to support preclinical activities. In addition, Parvus is eligible to receive downstream development, regulatory, and sales milestone payments, as well as product royalties. Novartis has also made an equity investment in Parvus.

T1D Navacims are composed of an iron oxide nanoparticle conjugated with multiple copies of a peptide derived from a pancreatic autoantigen, presented in the context of an MHC molecule. Preclinical studies have shown that Navacims achieve their therapeutic effect by reprogramming cognate pathogenic T cells into tissue-specific beneficial T-regs and thereafter inducing their systemic expansion. The expanded T-regs target and suppress the autoimmune disease-causing immune cells, sparing other immune cells and restoring the immune system to the normal steady state. Navacims have the potential, therefore, to specifically treat the autoimmune disease without increasing the risk of infection.

“This is a transformative collaboration for Parvus. We are excited by this strong endorsement of the science behind our Navacim platform, as well as the opportunity to collaborate closely with a globally recognized leader in the field of immunology and autoimmune disease,” stated Janice M. LeCocq, CEO of Parvus. "This will augment our resources across the Navacim platform and accelerate the development of our T1D program. We are also pursuing the development of multiple Navacims that target autoimmune diseases where there is high unmet need for disease-modifying drugs without causing systemic immunosuppression.”

About T1D
Type 1 diabetes (T1D) is caused by a chronic, progressive autoimmune response against the insulin-producing beta cells of the pancreas that ultimately leads to insulin-deficiency and high blood glucose levels. As a result, patients with T1D require insulin replacement therapy, usually involving multiple injections of insulin on a daily basis. Unfortunately, insulin is not a cure and does not treat the underlying cause of T1D. In addition, insulin replacement therapy cannot mimic the exquisitely tight control of glucose levels achieved by endogenous insulin production and, with time, can lead to serious complications, including blindness, stroke, myocardial failure, amputation and peripheral neuropathy. Currently, as many as 1.25 million Americans have T1D and the incidence of disease is steadily increasing. T1D is typically first diagnosed in children and young adults.

About Parvus Therapeutics Inc.
Parvus Therapeutics Inc. is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune complexes that induce the in vivo expansion of specific regulatory cells resulting in the restoration of immune homeostasis. Navacims can be readily tailored to target a broad range of autoimmune diseases and have the potential to radically improve the lives of patients suffering from these diseases. Navacims were discovered by Pere Santamaria, M.D., Ph.D. Chief Scientific Officer and Founder of Parvus, and Julia McFarlane, Diabetes Research Professor of the Cumming School of Medicine at the University of Calgary and Group Leader at Institut D’Investigacions Biomediques August Pi i Sunyer.

Media Inquiries:
Justin Jackson
212-213-0006, ext. 327
jjackson@burnsmc.com

Stakeholders & Partners

Loading...